top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
AIDS [[electronic resource]]
AIDS [[electronic resource]]
Autore Aggleton Peter
Pubbl/distr/stampa Hoboken, : Taylor and Francis, 1995
Descrizione fisica 1 online resource (237 p.)
Disciplina 362.1/969792
Altri autori (Persone) DaviesPeter (Peter M.)
HartGraham <1957->
Collana Social Aspects of AIDS
Soggetto topico AIDS (Disease)
AIDS (Disease) - Social aspects
HIV Infections
Sociology
Slow Virus Diseases
Probability
Acquired Immunodeficiency Syndrome
Risk
Social Environment
Virus Diseases
Statistics as Topic
Lentivirus Infections
Sexually Transmitted Diseases, Viral
Mathematical Concepts
Social Sciences
Immunologic Deficiency Syndromes
Phenomena and Processes
Sexually Transmitted Diseases
Anthropology, Education, Sociology and Social Phenomena
Diseases
Health Care Evaluation Mechanisms
Retroviridae Infections
Immune System Diseases
Epidemiologic Methods
Quality of Health Care
Investigative Techniques
Public Health
RNA Virus Infections
Environment and Public Health
Analytical, Diagnostic and Therapeutic Techniques and Equipment
Health Care Quality, Access, and Evaluation
Health Care
Communicable Diseases
Health & Biological Sciences
Soggetto genere / forma Electronic books.
ISBN 9982-19-047-4
0-203-36253-5
1-135-74692-3
1-280-02179-9
9786610021796
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Book Cover; Title; Contents; Preface; Reputedly Effective Risk Reduction Strategies and Gay Men; HIV-Related Discrimination in Medical Teaching Texts; Travel, Sexual Behaviour and Gay Men; Sexual Behaviour in Gay Men: Towards a Sociology of Risk; Framing Difference: Sexuality, AIDS and Organization; Towards Effective Inter vention: Evaluating HIV Prevention and Sexual Health Education Interventions; Communities, Governments and AIDS: Making Partnerships Work; Socially Apart Youth: Priorities for HIV Prevention
Theorizing and Researching 'Risk': Notes on the Social Relations of Risk in Heroin Users' LifestylesSex, Love and Seropositivity: Balancing the Risks; One of Us, One of Them, or One of Those? The Construction of Identity and Sexuality in Relation to HIV/AIDS; Sexuality, Identity and Community; Reflections on the MESMAC Project; Discourses of Power and Empowerment in the Fight Against HIV/AIDS in Africa; Notes on Contributors; Index
Record Nr. UNISA-996207278803316
Aggleton Peter  
Hoboken, : Taylor and Francis, 1995
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
AIDS : the making of a chronic disease
AIDS : the making of a chronic disease
Pubbl/distr/stampa [Place of publication not identified], : University of California Press, 1992
Disciplina 614.5/993
Soggetto topico AIDS (Disease) - History
Financial Support
Health Personnel
Homosexuality
Mass Media
Social Control, Formal
State Government
Substance-Related Disorders
Blood Donors
Confidentiality
Delivery of Health Care
Government
Acquired Immunodeficiency Syndrome
Blood Transfusion
Education
History
Legislation
Local Government
Health Policy
Hemophilia A
Human Experimentation
Jurisprudence
Public Health
Minority Groups
Federal Government
Government Regulation
HIV Seropositivity
Public Policy
International Cooperation
Developing Countries
Chronic Disease
Women
Politics
AIDS Serodiagnosis
Ethics, Medical
Internationality
Pharmaceutical Preparations
Employment
Poverty
Prejudice
Epidemiology
Publication Formats
Patient Care Management
Tissue Donors
Environment and Public Health
Economics
Health Care Facilities, Manpower, and Services
Medicine
Patient Rights
Forensic Psychiatry
Diseases
Health
Sociology
Disease Attributes
Persons
HIV Infections
Blood Coagulation Disorders, Inherited
Social Control Policies
Health Care Quality, Access, and Evaluation
Investigative Techniques
Biological Therapy
Serologic Tests
Organizations
Social Sciences
Sexuality
Coagulation Protein Disorders
Anthropology, Education, Sociology and Social Phenomena
Humanities
Psychology, Social
Social Problems
Hemorrhagic Disorders
Socioeconomic Factors
Health Care Economics and Organizations
Chemicals and Drugs
Ethics, Clinical
Research
Slow Virus Diseases
Occupational Groups
Biomedical Research
Communications Media
Mental Disorders
Health Care
Genetic Diseases, Inborn
Policy
Behavior and Behavior Mechanisms
Immunologic Deficiency Syndromes
Human Rights
Immunologic Tests
Science
Sexually Transmitted Diseases, Viral
Population Characteristics
Therapeutics
Virus Diseases
Psychiatry and Psychology
Publication Characteristics
Sexual Behavior
Psychiatry
Reproductive Physiological Phenomena
Health Services Administration
Named Groups
Information Science
Analytical, Diagnostic and Therapeutic Techniques and Equipment
Ethics, Professional
Blood Coagulation Disorders
Pathologic Processes
Lentivirus Infections
Hematologic Diseases
Health Occupations
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ethics
Immunologic Techniques
Sexually Transmitted Diseases
Immune System Diseases
Laboratory Techniques and Procedures
Behavior
Pathological Conditions, Signs and Symptoms
Retroviridae Infections
Hemic and Lymphatic Diseases
Reproductive and Urinary Physiological Phenomena
Natural Science Disciplines
Disciplines and Occupations
Behavioral Sciences
RNA Virus Infections
Diagnosis
Phenomena and Processes
Behavioral Disciplines and Activities
Communicable Diseases
Health & Biological Sciences
ISBN 0-520-07569-2
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Altri titoli varianti AIDS
Record Nr. UNINA-9910495891403321
[Place of publication not identified], : University of California Press, 1992
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Alcohol consumption and cancer risk : understanding possible causal mechanisms for breast and colorectal cancers
Alcohol consumption and cancer risk : understanding possible causal mechanisms for breast and colorectal cancers
Pubbl/distr/stampa [Place of publication not identified], : Agency for Healthcare Research and Quality, 2010
Descrizione fisica 1 online resource (ix, 81 p.)
Collana AHRQ Publication
Evidence Report/Technology Assessment
Soggetto topico Risk
Breast Diseases
Drinking Behavior
Colonic Diseases
Intestinal Neoplasms
Causality
Neoplasms by Site
Rectal Diseases
Gastrointestinal Neoplasms
Neoplasms
Probability
Intestinal Diseases
Behavior
Epidemiologic Factors
Skin Diseases
Diseases
Behavior and Behavior Mechanisms
Gastrointestinal Diseases
Statistics as Topic
Skin and Connective Tissue Diseases
Digestive System Neoplasms
Quality of Health Care
Public Health
Digestive System Diseases
Environment and Public Health
Epidemiologic Methods
Health Care Quality, Access, and Evaluation
Health Care Evaluation Mechanisms
Health Care
Investigative Techniques
Diagnostic Techniques and Procedures
Breast Neoplasms
Risk Factors
Colorectal Neoplasms
Alcohol Drinking
Medicine
Health & Biological Sciences
Oncology
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910703239203321
[Place of publication not identified], : Agency for Healthcare Research and Quality, 2010
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
Autore Organization World Health
Pubbl/distr/stampa Geneva, : World Health Organization, 2014
Descrizione fisica 1 online resource (254 p.)
Disciplina 616
Soggetto topico Drug resistance -- Periodicals
Drug resistance in microorganisms
Drug resistance
Anti-infective agents - Classification
Drug resistance in microorganisms - Effect of drugs on
Risk management
Risk
Risk Management
Information Science
Drug Resistance
Microbiological Phenomena
Epidemiologic Measurements
Therapeutic Uses
Probability
Pharmacologic Actions
Pharmacological Phenomena
Public Health
Organization and Administration
Statistics as Topic
Health Services Administration
Environment and Public Health
Chemical Actions and Uses
Physiological Phenomena
Health Care Evaluation Mechanisms
Health Care
Epidemiologic Methods
Drug Therapy
Quality of Health Care
Investigative Techniques
Diagnostic Techniques and Procedures
Health Care Quality, Access, and Evaluation
Anti-Infective Agents
Classification
Risk Assessment
Drug Resistance, Microbial
Biology
Health & Biological Sciences
Microbiology & Immunology
Soggetto genere / forma Electronic books.
Publication Formats
Technical Report
ISBN 92-4-069266-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References
SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment
4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses
4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine
5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material
Record Nr. UNINA-9910511992203321
Organization World Health  
Geneva, : World Health Organization, 2014
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
Autore Organization World Health
Pubbl/distr/stampa Geneva, : World Health Organization, 2014
Descrizione fisica 1 online resource (254 p.)
Disciplina 616
Soggetto topico Drug resistance -- Periodicals
Drug resistance in microorganisms
Drug resistance
Anti-infective agents - Classification
Drug resistance in microorganisms - Effect of drugs on
Risk management
Risk
Risk Management
Information Science
Drug Resistance
Microbiological Phenomena
Epidemiologic Measurements
Therapeutic Uses
Probability
Pharmacologic Actions
Pharmacological Phenomena
Public Health
Organization and Administration
Statistics as Topic
Health Services Administration
Environment and Public Health
Chemical Actions and Uses
Physiological Phenomena
Health Care Evaluation Mechanisms
Health Care
Epidemiologic Methods
Drug Therapy
Quality of Health Care
Investigative Techniques
Diagnostic Techniques and Procedures
Health Care Quality, Access, and Evaluation
Anti-Infective Agents
Classification
Risk Assessment
Drug Resistance, Microbial
Biology
Health & Biological Sciences
Microbiology & Immunology
Soggetto genere / forma Publication Formats
Technical Report
ISBN 92-4-069266-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References
SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment
4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses
4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine
5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material
Record Nr. UNINA-9910786624203321
Organization World Health  
Geneva, : World Health Organization, 2014
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
Autore Organization World Health
Pubbl/distr/stampa Geneva, : World Health Organization, 2014
Descrizione fisica 1 online resource (254 p.)
Disciplina 616
Soggetto topico Drug resistance -- Periodicals
Drug resistance in microorganisms
Drug resistance
Anti-infective agents - Classification
Drug resistance in microorganisms - Effect of drugs on
Risk management
Risk
Risk Management
Information Science
Drug Resistance
Microbiological Phenomena
Epidemiologic Measurements
Therapeutic Uses
Probability
Pharmacologic Actions
Pharmacological Phenomena
Public Health
Organization and Administration
Statistics as Topic
Health Services Administration
Environment and Public Health
Chemical Actions and Uses
Physiological Phenomena
Health Care Evaluation Mechanisms
Health Care
Epidemiologic Methods
Drug Therapy
Quality of Health Care
Investigative Techniques
Diagnostic Techniques and Procedures
Health Care Quality, Access, and Evaluation
Anti-Infective Agents
Classification
Risk Assessment
Drug Resistance, Microbial
Biology
Health & Biological Sciences
Microbiology & Immunology
Soggetto genere / forma Publication Formats
Technical Report
ISBN 92-4-069266-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References
SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment
4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses
4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine
5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material
Record Nr. UNINA-9910825162403321
Organization World Health  
Geneva, : World Health Organization, 2014
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
Autore Kazmierski Wieslaw M
Pubbl/distr/stampa Hoboken, : Wiley, 2011
Descrizione fisica 1 online resource (470 p.)
Disciplina 615/.7924
Soggetto topico Antiviral Agents -- therapeutic use
Antiviral agents
Clinical Trials as Topic
Drug Discovery
Drug Evaluation
Epidemiologic Studies
Chemistry, Pharmaceutical
Evaluation Studies as Topic
Investigative Techniques
Anti-Infective Agents
Epidemiologic Methods
Pharmacology
Therapeutic Uses
Health Care Evaluation Mechanisms
Chemistry
Biological Science Disciplines
Natural Science Disciplines
Quality of Health Care
Public Health
Pharmacologic Actions
Environment and Public Health
Health Care Quality, Access, and Evaluation
Chemical Actions and Uses
Health Care
Antiviral Agents
Health & Biological Sciences
Pharmacy, Therapeutics, & Pharmacology
ISBN 1-283-20363-4
9786613203632
0-470-92935-9
0-470-92934-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir
14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection
21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir
29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate
Record Nr. UNINA-9910139613803321
Kazmierski Wieslaw M  
Hoboken, : Wiley, 2011
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
Autore Kazmierski Wieslaw M
Pubbl/distr/stampa Hoboken, : Wiley, 2011
Descrizione fisica 1 online resource (470 p.)
Disciplina 615/.7924
Soggetto topico Antiviral Agents -- therapeutic use
Antiviral agents
Clinical Trials as Topic
Drug Discovery
Drug Evaluation
Epidemiologic Studies
Chemistry, Pharmaceutical
Evaluation Studies as Topic
Investigative Techniques
Anti-Infective Agents
Epidemiologic Methods
Pharmacology
Therapeutic Uses
Health Care Evaluation Mechanisms
Chemistry
Biological Science Disciplines
Natural Science Disciplines
Quality of Health Care
Public Health
Pharmacologic Actions
Environment and Public Health
Health Care Quality, Access, and Evaluation
Chemical Actions and Uses
Health Care
Antiviral Agents
Health & Biological Sciences
Pharmacy, Therapeutics, & Pharmacology
ISBN 1-283-20363-4
9786613203632
0-470-92935-9
0-470-92934-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir
14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection
21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir
29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate
Record Nr. UNINA-9910808713803321
Kazmierski Wieslaw M  
Hoboken, : Wiley, 2011
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Antropologia dell'olfatto / / Alessandro Gusman
Antropologia dell'olfatto / / Alessandro Gusman
Autore Gusman Alessandro
Pubbl/distr/stampa Roma [etc.], : GLF editori Laterza, 2004
Descrizione fisica ix, 183 p. ; ; 21 cm
Disciplina 301
152
306
612
Collana Antropologia
Percorsi
Soggetto topico Sensation
Environment
Anthropology
Psychophysiology
Environment and Public Health
Nervous System Physiological Processes
Social Sciences
Ecological and Environmental Phenomena
Biological Phenomena
Health Care
Nervous System Physiological Phenomena
Psychological Phenomena and Processes
Anthropology, Education, Sociology and Social Phenomena
Psychiatry and Psychology
Musculoskeletal and Neural Physiological Phenomena
Phenomena and Processes
Odors
Smell
Anthropology, Cultural
ISBN 88-581-1860-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione ita
Record Nr. UNINA-9910132989503321
Gusman Alessandro  
Roma [etc.], : GLF editori Laterza, 2004
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]]
Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]]
Autore Boverhof Darrell R
Pubbl/distr/stampa Hoboken, : Wiley, 2011
Descrizione fisica 1 online resource (402 p.)
Disciplina 616.042
616/.042
Altri autori (Persone) GollapudiB. Bhaskar
Soggetto topico Genetic toxicology
Health risk assessment
Risk Assessment
Toxicity testing
Toxicogenetics
Toxicology
Pharmacogenetics
Risk
Risk Management
Epidemiologic Measurements
Organization and Administration
Pharmacology
Probability
Genetics
Public Health
Health Occupations
Statistics as Topic
Biological Science Disciplines
Biology
Health Services Administration
Environment and Public Health
Natural Science Disciplines
Health Care
Health Care Evaluation Mechanisms
Epidemiologic Methods
Quality of Health Care
Investigative Techniques
Health Care Quality, Access, and Evaluation
Health & Biological Sciences
Toxicology & Public Health
Soggetto genere / forma Electronic books.
ISBN 1-283-23966-3
9786613239662
1-118-00104-4
1-118-00103-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Contents; Preface; Contributors; 1 Toxicology, ""Omics"" Technologies, and Toxicogenomics: A Primer; 2 Introduction to Human Health Risk Assessment; 3 Practical Considerations for the Application of Toxicogenomics to Risk Assessment: Early Experience, Current Drivers, and a Path Forward; 4 Approaches and Practical Considerations for the Analysis of Toxicogenomics Data; 5 Genomics in Identifying Mutagenic Mode of Action in Carcinogenesis; 6 Application of Genomics for Predicting and Understanding the Mode of Action for Nongenotoxic Carcinogens; 7 Genomics in Characterizing Endocrine Toxicity
8 Studying Organ-Specific Toxicity Using Gene-Expression Profiling9 Toxicogenomic Studies in Human Populations; 10 Toxicogenomics Applied to Ecological Risk Assessment; 11 Analysis of Transcriptomic Dose-Response Data for Toxicology and Risk Assessment; 12 Toxicogenomics as a Tool for Validating Animal to Human Extrapolations in Chemical Risk Assessment: Concepts, Applications, and Challenges; 13 Toxicogenomics and Animal Alternatives; 14 Toxicogenomics and the Regulatory Framework; 15 Standardization of Gene-Expression Information for the Safety Evaluation: Activities in Japan
16 Applying Transcriptional Profiling in Drug Safety Evaluation17 Reframing the Risk Assessment Paradigm: Toward a Systems Biology Approach; Index
Record Nr. UNINA-9910139607903321
Boverhof Darrell R  
Hoboken, : Wiley, 2011
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui